Cited by 187Fungal Infections and StudiesAntifungal resistance and susceptibilityBacterial Infections and Vaccines

Protection against Cryptococcosis by Using a Murine Gamma Interferon-Producing Cryptococcus neoformans Strain

Open access
Wormley, Floyd L., Perfect, John R., Steele, Chad, Cox, Gary M.·2007·Infection and Immunity

Abstract

We evaluated cell-mediated immune (CMI) responses in mice given a pulmonary infection with a Cryptococcus neoformans strain engineered to produce the Th1-type cytokine gamma interferon (IFN-γ). Mice given a pulmonary infection with an IFN-γ-producing C. neoformans strain were able to resolve the primary infection and demonstrated complete (100%) protection against a second pulmonary challenge with a pathogenic C. neoformans strain. Pulmonary cytokine analyses showed that Th1-type/proinflammatory cytokine and chemokine expression were significantly higher and Th2-type cytokine expression was significantly lower in mice infected with the IFN-γ-producing C. neoformans strain compared to wild-type-infected mice. This increased pulmonary Th1-type cytokine expression was also associated with significantly lower pulmonary fungal burden and significantly higher pulmonary leukocyte and T-lymphocyte recruitment in mice infected with the IFN-γ-producing C. neoformans strain compared to wild-type-infected mice. Our results demonstrate that pulmonary infection of mice with a C. neoformans strain expressing IFN-γ results in the stimulation of local Th1-type anti-cryptococcal CMI responses and the development of protective host immunity against future pulmonary cryptococcal infections. The use of fungi engineered to produce host cytokines is a novel method to study immune responses to infection and may be useful in developing vaccine strategies in humans.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1128/iai.00274-06

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Immunization with a C. neoformans strain genetically engineered to produce IFNγ (H99γ) induced protective immunity in mice depleted of CD4+ T cells.

    “Interestingly, in a mouse model of cryptococcosis, immunization with a C. neoformans strain that was genetically engineered to produce IFNγ (H99γ) induced protective immunity in mice depleted of CD4+ T cells133,134.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 44 · Cited by 187

Research works printed but not linked: 3

  1. [4]Chuck, S. L., and M. A. Sande. 1989. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N. Engl. J. Med. 321:794-799. [DOI] [PubMed] [Google Scholar]
  2. [7]Collins, V. P., A. Gellhorn, and J. R. Trimble. 1995. The coincidence of cryptococcosis and disease of the reticulo-endothelial and lymphatic systems. Cancer 4:883-889. [DOI] [PubMed] [Google Scholar]
  3. [23]Keye, J. D., and W. E. Magee. 1956. Fungal diseases in a general hospital. Am. J. Clin. Pathol. 26:1235-1253. [DOI] [PubMed] [Google Scholar]

Authors
Wormley, F. L., Perfect, J. R., Steele, C., & Cox, G. M.
Affiliations
  • Duke University (US)
  • University of Pittsburgh (US)
Corresponding author
Wormley, Floyd L.
Venue
Infection and Immunity
Published
2007-03
Volume
75
Issue
3
Pages
1453-1462
ISSN
  • 0019-9567 (ISSN-L)
  • 1098-5522
OpenAlex
W2171953577
Cited by
187
References
44
Citations by year
2026: 3 · 2025: 12 · 2024: 11 · 2023: 13 · 2022: 16 · 2021: 8 · 2020: 6 · 2019: 15 · 2018: 12 · 2017: 9 · 2016: 9 · 2015: 18 · 2014: 12 · 2013: 10 · 2012: 8
FWCI
3.68
Type
journal article
Language
en
Open access
Locations
  • Infection and Immunity (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (AI007392)
  • Center for AIDS Research, Duke University (P30-AI-64518)
  • Center for AIDS Research, University of Washington
  • National Institute of Allergy and Infectious Diseases (AI007392, P30AI 64518, R56AI028388, AI28388, R01AI028388, AI 39156, AI1062563, U01AI039156, P30AI064518, T32AI007392)
Topics
  • Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords
cryptococcosis, Cryptococcus neoformans, interferon-gamma, Th1 response, cell-mediated immunity, pulmonary infection, fungal vaccines, cytokine expression, chemokines, T cell recruitment, fungal burden, protective immunity
MeSH terms
Animals, Cryptococcosis, Cryptococcus neoformans, Female, Interferon-gamma, Mice, Inbred A, Mice, Inbred BALB C, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review